Funding profile · Digital pathology

Morphle Labs

A Delaware parent with an Indian operating subsidiary, roughly $5.15 million raised across three rounds, and no Form D on file with the SEC. The audited numbers that exist are Indian, not American.

$5.0MSeries A led by Inflexor Ventures, announced Nov 25, 2025
$5.15MTotal across 3 rounds, per Tracxn
Rs 14.25 CrFY2024 revenue of the Indian subsidiary, up 29 percent
0Form D notices filed with the SEC

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2019 Competition prize $75,000 HealthVenture, at C-CAMP’s National Bio Entrepreneurship Competition Founder interview
Mar 2020 Seed, Y Combinator Winter 2020 Not disclosed Y Combinator YC and Tracxn
Nov 25, 2025 Series A $5,000,000 Led by Inflexor Ventures. No co-investor named in any account. Press and investor site
Total to date Three rounds $5.15M Aggregator count; Parsers VC also lists Enzia Ventures, which no primary account confirms Aggregator

What the filings show

Morphle Labs Private Limited · MCA annual filings · ROC Bangalore

CIN
U29309KA2020PTC131387
Incorporated
Jan 8, 2020
Status
Subsidiary of Morphle Labs Inc, USA · DPIIT recognised startup
Capital
Authorised Rs 20.2 lakh · paid up Rs 1.22 lakh
Revenue
Rs 14.25 crore for FY2024, up 29 percent year on year
Directors
Rohit Ramesh Hiwale (since Jan 8, 2020); Ashish Hariram Manmode (since Oct 21, 2021)
Charges
None registered with the Registrar
Last AGM
Oct 30, 2025 · statements filed for the year ended Mar 31, 2025

Morphle Labs Inc · FDA establishment registration 3033165977

Address
16192 Coastal Highway, Lewes, Delaware 19958
Type
Develop Specifications But Do Not Manufacture At This Facility
Listed device
ROBOTOME, created Dec 9, 2024
Product code
IDO, Microtome, Rotary · 21 CFR 864.3010 · device class 1
Clearances
No 510(k) number and no PMA number attached
Correspondent
Sunnel Daniel, chief operating officer

Securities filings · SEC EDGAR

Form D
None found for Morphle Labs Inc
Vehicles
No SPV or fund naming the company found
Reading
Consistent with a US holding company whose financing was raised in India or under Section 4(a)(2)

Reading the filings

  1. The capital is small against the ambition.Total disclosed funding is about $5.15 million for a company that designs, manufactures and services precision robotics in two countries, and that says it employs about 100 people. Philips, Leica, Hamamatsu and Roche, the holders of FDA cleared whole slide imaging systems, are divisions of multibillion dollar groups.
  2. The revenue line matters more than the round.Rs 14.25 crore for FY2024 is roughly $1.7 million at 2024 rates, and it grew 29 percent. That is one of the few audited figures anywhere in this file, and it belongs to the Indian subsidiary alone. Consolidated group revenue is not public.
  3. No Form D is not the same as no US money.Morphle Labs Inc is a Delaware entity, but no Regulation D notice appears for it. Companies that raise under Section 4(a)(2), or that raise into an Indian entity, file none. The absence is a gap in the record, not evidence of absence.
  4. The round is dated two ways.Every press account puts the Series A on Nov 25, 2025. Tracxn dates it Sep 25, 2025, two months earlier. The same aggregator dates the HealthVenture prize to Sep 11, 2021, which is the publication date of an article reporting a 2019 competition. Treat aggregator dates as reporting dates, not closing dates.
  5. The money is explicitly for regulatory work.Business Standard, YourStory and Tech Observer all report the proceeds going to manufacturing scale, IP and global regulatory approvals. That is the tell: the company is buying its way toward clearances it does not hold, in the markets it wants next.
  6. Balance sheet risk is low, execution risk is not.The Indian subsidiary has no charges registered with the Registrar, meaning no secured lender has a claim on it. The company also just won a patent fight it did not choose, now on appeal.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k) or PMA. RoboTome listed as a Class I rotary microtome since Dec 2024. Company says it is pursuing clearance for the Morpholens 400. Public record
Litigation OptraSCAN patent suits in W.D. Texas and D. Delaware. Final judgment for Morphle Jan 21, 2026; appeal docketed at the Federal Circuit Feb 2026. Public record
Installed base 250 or more laboratories across 20 or more countries per the website; more than 30 countries per the chief executive in Nov 2025. Not independently counted. Company-stated
Pricing Hardware listed from $17,000, against high volume scanners from incumbent vendors. Company-stated
Channel Deep Bio software partnership since 2021. Technopath lists the RoboTome RTM30. MedicalExpo carries the scanner catalogue. Partner-stated
Clinical evidence No peer reviewed study, no registered trial, no published concordance data. Not found

What to watch

  • A Form D, if any part of the next round is sold into US investors from the Delaware entity.
  • FY2025 revenue for Morphle Labs Private Limited, filed with the MCA.
  • A 510(k) number appearing against the Morpholens 400.
  • The Federal Circuit appeal, docket 26-1461.
  • Whether the Series A is extended, and whether Inflexor is joined by a strategic buyer of diagnostics hardware.

The Morphle Labs story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Equipt Health: Shared investor: Parsers Vc. A Y Combinator company that set out to be the missing logistics layer for prescription medical devices at home, and sold sleep apnea care direct to patients as Helio
  • Perceptive Technologies: Also in Medical Devices. A handheld scanner that sees inside a tooth with infrared light instead of X-rays, and a robot arm that cuts the tooth
  • NearWave: Also in Medical Devices. A handheld near infrared scanner built to tell an oncologist within a week whether chemotherapy is working on a breast tumor
  • Revolve Surgical: Also in Medical Devices. A Toronto company building a laparoscopic robot that clamps to the operating table instead of filling the room

Sources

  1. Public recordopenFDA registration and listing, Morphle Labs Inc, 3033165977FDA · current to Sep 14, 2026
  2. Public recordopenFDA 510(k) and PMA queries returning no Morphle recordsFDA · Sep 23, 2026
  3. Public recordMorphle Labs Private Limited, CIN U29309KA2020PTC131387The Company Check, from MCA data · Feb 18, 2026
  4. Public recordOptraSCAN v. Morphle Labs, 1:23-cv-00733 and 1:24-cv-00649CourtListener RECAP · 2023 to 2026
  5. IndependentMorphle Labs raises $5 million to automate core of cancer diagnosticsBusiness Standard · Nov 25, 2025
  6. InterviewMorphle Labs raises $5 mn in Series A led by Inflexor VenturesEconomic Times B2B · Nov 25, 2025
  7. IndependentDeeptech startup Morphle Labs raises $5M in Series AYourStory · Nov 25, 2025
  8. AggregatorMorphle funding rounds and investorsTracxn · accessed Sep 23, 2026
  9. InterviewThis medtech startup aims to empower healthcare institutionsYourStory · Sep 11, 2021
  10. InvestorMorphle Labs raises $5 mn in Series A funding led by Inflexor VenturesInflexor Ventures · Nov 25, 2025
  11. CompanyThe FDA landscape in digital pathologyMorphle Labs knowledge base · accessed Sep 23, 2026
  12. CompanyRobotome and scanner product pages, pricing and installed base claimsMorphle Labs · accessed Sep 23, 2026

Compiled from FDA, US federal court and Indian Ministry of Corporate Affairs public records and published reports as of September 23, 2026. No Regulation D Form D notice was located for Morphle Labs Inc; reported round sizes are company or press figures and are labeled as such. Healthcare Venture Capital Fund holds no position in Morphle Labs. This page is not an offer to sell or a recommendation to buy any security.